We have Ranked, Sorted and Summarized the Latest Clinical Articles.

1High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational studyThe Lancet Oncology, July 06, 2015  Clinical Article
2Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9Breast Cancer Research and Treatment, July 06, 2015  Clinical Article
3Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)Annals of Oncology, July 06, 2015  Clinical Article
4Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysisSurgery, July 06, 2015  Clinical Article
5National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen–based screeningJournal of Clinical Oncology, July 06, 2015  Clinical Article
6Areca nut contributes to oral malignancy through facilitating the conversion of cancer stem cellsMolecular Carcinogenesis, July 06, 2015  Clinical Article
7Management of urogenital atrophy in breast cancer patients: A systematic review of available evidence from randomized trialsBreast Cancer Research and Treatment, July 06, 2015  Evidence Based Medicine  Review Article
8Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2)BMC Cancer, July 06, 2015  Full Text  Clinical Article
9High graft CD8 cell dose predicts improved survival and enables better donor selection in allogeneic stem-cell transplantation with reduced-intensity conditioningJournal of Clinical Oncology, July 06, 2015  Clinical Article
10Effect of sulfasalazine on human neuroblastoma: Analysis of sepiapterin reductase (SPR) as a new therapeutic targetBMC Cancer, July 06, 2015  Full Text  Clinical Article

Show Me:

We have Ranked, Sorted and Summarized the Latest Clinical Articles.

1Cancer survivors who smoke perceive less risk from tobacco than non-smoking survivorsAmerican Cancer Society News, July 06, 2015
2The "bad luck" explanation of cancer oversimplifies a complex diseaseUniversity of Colorado Health News, July 06, 2015
3V-Smart tech could be answer to brain tumor treatmentBen-Gurion University of the Negev News, July 06, 2015
4Body mass index impacts ovarian cancer chemotherapy dosagesKaiser Permanente Health Research News, July 06, 2015
5Singapore team's discovery of new genomic aberrations of gastric cancer could pave the way for precision medicineAgency for Science, Technology and Research (A*STAR) News, July 06, 2015
6Abdominal blood clots may indicate undiagnosed cancerAarhus University Health News, July 06, 2015
7World GI 2015: Studies confirm regorafenib benefit in pre-treated metastatic colorectal cancerEuropean Society for Medical Oncology News, July 06, 2015
8Discovery promises new treatments to thwart colon cancerSt. Jude Children's Research Hospital News, July 06, 2015
9Eighteen genes identified that contribute to childhood brain tumor ependymomaSt. Jude Children's Research Hospital News, July 06, 2015
10Cancer Today summer issue addresses financial strain of cancer treatmentAmerican Association for Cancer Research News, July 06, 2015

Show Me:

Cisplatin monotherapy effective in pediatric high-risk hepatoblastoma

As reported in the Journal of Pediatric Hematology/Oncology, treatment of children with high-risk hepatoblastoma (n=14) with cisplatin monotherapy was as effective as cisplatin + doxorubicin combination therapy, but with less toxicity. The complete resection rate was 78.6%, the event-free survival rate was 81.8%, and the OS rate was 100%.

YKL-40 predicts poor prognosis for bladder cancer

As reported in Urologic Oncology, the gene expression and serum level of YKL-40 are higher in patients with bladder cancer than healthy controls. Serum YKL-40 levels predict poor prognosis in patients with muscle-invasive bladder cancer (HR=1.75).

Increased incidence of second primary cancers in patients with salivary gland tumors

As reported in JAMA—Otolaryngology-Head & Neck Surgery, patients with salivary gland tumors have an increased risk of second primary tumors and newly developed cancers. Specifically, the cumulative 2-, 5-, and 10-year rates for second primary cancers are 4.4%, 8.3%, and 12.4%, respectively. Similarly, the cumulative 2-, 5-, and 10-year rates for newly diagnosed cancers are 1.1%, 3.4%, and 10.5%, respectively.

Are YOU the Smartest Doc in America?

The Smartest Doc from MDLinx keeps you current with a competitive edge, pitting colleagues against one other for the title of The Smartest Doc in America.

Take the Challenge

Clinical Pearls

Clinical Pearl from Smartest DocThe use of PET-CT in patients with N1 and N2 cancer unknown primary of the head and neck is the cost-effective choice.

Clinical Pearl from Smartest DocCixutumumab/temsirolimus treatment is not associated with objective responses in younger recurrent/refractory sarcoma patients.

Clinical Pearl from Smartest DocCombined TACE and sorafenib for hepatocellular carcinoma is tolerable and associated with a promising time to progression.

Be Ready for Upcoming 2015 Board Exams!

Be prepared for board reviews with confidence with 1000s of board exam style questions. Prepare Here